Chimerix, Inc.
2505 Meridian Parkway
Durham
North Carolina
27713
United States
Website: http://www.chimerix-inc.com/
327 articles about Chimerix, Inc.
-
Merck KGaA buys Amptec for mRNA tech and Chimerix acquires Oncoceutics for cancer pipeline.
-
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
1/8/2021
Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million
-
Chimerix to Present at Virtual H.C. Wainwright BioConnect 2021 Conference
1/6/2021
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2021 Conference made available on Monday, January 11, 2021 at 7:00 a.m. ET. An audio webcast of the presentation will be available on the Investor Relations
-
Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for SmallpoxFDA Grants Priority Review and Sets PDUFA Date for April 7, 2021
12/7/2020
Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that the U.S. Food and Drug Administration has accepted the filing of a New Drug Application for brincidofovir as a medical countermeasure for smallpox.
-
Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference
11/5/2020
Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at the Credit Suisse 29th Annual Healthcare Conference on Thursday, November 12, 2020 at 4:15 p.m. ET.
-
Chimerix Reports Third Quarter 2020 Financial Results and Provides Operational Update
11/5/2020
Completed Rolling NDA Submissions for Both BCV Tablet and SuspensionFormulations as Medical Countermeasure for Smallpox
-
Chimerix to Participate in Upcoming Investor Conferences
9/10/2020
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September
-
Chimerix Reports Second Quarter 2020 Financial Results and Provides Operational Update
8/10/2020
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the second quarter ended June 30, 2020 and provided an operational update.
-
Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020
8/3/2020
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Monday, August 10, 2020 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2020, and to provide a business overview. To access the live conference call, please dial (877) 354-4056 (domestic)
-
Chimerix Appoints Allen Melemed, M.D. as Chief Medical OfficerFormer Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise
6/22/2020
Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced the appointment of Allen Melemed, M.D., M.B.A., as Chief Medical Officer.
-
Chimerix to Present at H.C. Wainwright Virtual Fireside Chat Series
6/18/2020
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Company management, including Mike Sherman, Chief Executive Officer, and Mike Andriole, Chief Business and Financial Officer, will participate in a fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, 2020 at 12:05 p.m. ET.
-
Chimerix to Present at Jefferies Virtual Healthcare Conference
5/28/2020
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 9:30 a.m. ET. A live audio webcast of the presentation will be available on the Investor Relations section of C
-
Chimerix Reports First Quarter 2020 Financial Results and Provides Operational Update
5/7/2020
DSTAT Explored as a Potential Novel Treatment for the Current Pandemic While an NDA is Being Prepared for Brincidofovir to Address a Potential Future Pandemic
-
Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19
4/29/2020
Mechanisms of Action May Address Overactive Inflammatory Response, Including Underlying Causes of Blood Coagulation Disorders Associated with COVID-19
-
Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
4/28/2020
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) for a rolling submission of its New Drug Application (NDA) for the approval of brincidofovir (BCV) as a medical countermeasure for smallpox.
-
Chimerix to Present at Cowen and Company 40th Annual Health Care Conference
2/26/2020
DURHAM, N.C., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4, 2020 at 8:40 a.m. ET in Boston, MA. A live audio webcast of the presentation will be available on the Investor Relations s
-
Chimerix Reports Fourth Quarter and Year End 2019 Financial Results and Provides Operational Update
2/25/2020
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2019 and provided an operational update.
-
Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors
2/24/2020
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced the appointment of Pratik S. Multani, M.D., to its Board of Directors, effective immediately.
-
Chimerix to Report Fourth Quarter and Year End 2019 Financial Results and Provide an Operational Update on February 25, 2020
2/18/2020
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Tuesday, February 25, 2020 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2019
-
Chimerix Presents Data Supporting Brincidofovir as a Potential Treatment for Smallpox at 2020 American Society for Microbiology Biothreats Meeting
1/29/2020
Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection